WebApr 26, 2024 · In the phase 3 OVAL trial, women with recurrent, platinum-resistant ovarian cancer were randomized to receive paclitaxel in combination with either ofra-vec or placebo. In addition to the dual primary end points, secondary outcome measures include objective response rate and response by CA-125 levels. WebJun 15, 2024 · OVAL is an international Phase 3 randomized pivotal registration enabling clinical trial that compares a combination of VB-111 and paclitaxel to placebo plus paclitaxel, in patients with platinum ...
Ofranergene obadenovec (VB-111) in platinum-resistant …
WebAug 12, 2024 · The independent data safety monitoring committee (DMSC) has unanimously recommended that the phase 3 OVAL trial (NCT03398655) examining VB-111 … WebSep 3, 2024 · The Oval ovarian cancer trial has currently recruited about 80% of its 400 patient target. VB-111, or ofranergene obadenovec, is a gene therapy delivered by adenovirus. It targets both tumor... how to install a chlorinator on pool
VBL Therapeutics Announces Completion of Enrollment in OVAL
Web8 hours ago · Norwood Oval adds a bit of charm. Gather Round had another massive test in front of it as the Suns and Dockers ran onto an Adelaide suburban footy ground in an … WebMar 8, 2024 · OVAL (VB-111-701/GOG-3018) is an international Phase 3 randomized, pivotal registration-enabling clinical trial comparing a combination of ofra-vec (ofranergene obadevovec or VB-111) and paclitaxel to placebo plus paclitaxel, in adult patients with recurrent platinum-resistant ovarian cancer. WebJul 20, 2024 · The phase 3 OVAL trial (NCT03398655) of ofranergene obadenovec (VB-111; VBL Therapeutics) in combination with paclitaxel has failed to meet its primary endpoint in improving progression-free survival (PFS) or overall survival (OS) in patients with platinum-resistant ovarian cancer. 1 how to install a chimney liner uk